logo
Plus   Neg
Share
Email

FUCHS Group Agrees To Buy Business Of ZIMMARK

Lubricant manufacturer Fuchs Petrolub AG (FUPEF.PK) announced that it has agreed to
buy the business of ZIMMARK INC. The transaction will be effective November 1, 2019.

Fuchs stated that the business will operate as a separate Chemicals Process Management (CPM) Division of FUCHS' North American industrial business.

The Burlington, Ontario, Canada based ZIMMARK is a service company offering value added services in the lubricants and Chemicals Process Management (CPM) space.

With this acquisition the FUCHS Group expands its service portfolio in the
industrial lubricant market and will deploy its processes where applicable
throughout its other global divisions.

"The acquisition, and especially the ZIMMARK team, will significantly enlarge our service offering capability to existing business along with offering value added services to new customers using FUCHS'marketplace presence." said Keith Brewer, President & CEO of FUCHS LUBRICANTS CO., USA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT